Apollomics, Inc. (NASDAQ:APLM – Get Free Report) shares rose 7.4% during trading on Thursday . The stock traded as high as $7.99 and last traded at $7.26. Approximately 38,635 shares traded hands during trading, a decline of 61% from the average daily volume of 99,412 shares. The stock had previously closed at $6.76.
Apollomics Stock Performance
The firm has a 50-day moving average price of $6.44 and a 200 day moving average price of $8.25.
About Apollomics
Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.
Read More
- Five stocks we like better than Apollomics
- 5 Top Rated Dividend Stocks to Consider
- Turbulence for Joby Shares: What’s Behind the Recent Dip?
- How Investors Can Find the Best Cheap Dividend Stocks
- Why Carnival Could Be the Ultimate Non-Tech Growth Stock
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Super Micro Computer Stock Clears New Path Higher on Saudi Orders
Receive News & Ratings for Apollomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollomics and related companies with MarketBeat.com's FREE daily email newsletter.
